Semaglutide

Semaglutide

Semaglutide (Ozempic, Wegovy)

GLP-1 agonist — weight loss and glycemic control

Fat Loss ★ 98 FDA Approved
Half-life
~7 days
Cycle
Not cycled — long-term use. Taper gradually if discontinuing.
Storage
Prescription product: refrigerated. Compounded: 2-8°C, 30-56 days after reconstitution.
Research
FDA approved (Wegovy 2021 for obesity)

About

A GLP-1 receptor agonist, FDA-approved for type 2 diabetes and obesity. One of the most effective weight-loss medications available.

Mechanism

Mimics GLP-1, increases insulin, suppresses glucagon, slows gastric emptying, reduces appetite.

Dosage

0.25 mg
1x per week for 4 weeks
0102030405060708090100

Draw to 10 units on a U-100 insulin syringe

5 mg · 2 mL BAC

Route
SubQ
Duration
Titration phase

When to take: Same day each week. Timing relative to meals matters little.

Reconstitution

Vial size (mg): 5 mg · BAC water (mL): 2 mL · Concentration: 2.5 mg/mL

Store refrigerated after reconstitution, 30 days.

Benefits

  • 15-20% weight loss (STEP trials)
  • Improved glycemic control
  • Lowered HbA1c
  • Reduced cardiovascular risk (SELECT trial)
  • Reduces appetite and 'food noise'

Side effects

  • Nausea (common initially)
  • Diarrhea / constipation
  • Reflux
  • Fatigue
  • Rare: gallstones, pancreatitis

Gender notes

Same dose, same efficacy.

Cautions

  • Medullary thyroid carcinoma (history)
  • MEN 2 syndrome
  • Pregnancy
  • History of pancreatitis

Research

Stacks well with

BPC-157Ipamorelin
Add reminder Calculator